Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

147.19 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 689
Open 147.19
Bid (Size) 147.35 (1)
Ask (Size) 147.83 (12)
Prev. Close 147.19
Today's Range 147.19 - 147.19
52wk Range 143.13 - 175.97
Shares Outstanding 2,628,679,824
Dividend Yield 3.23%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Johnson & Johnson the Best Dividend Stock for You?
J&J is the textbook blue chip stock -- but it's not for everyone. 
Via The Motley Fool
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism in Iraq, dismissing a lower court's ruling and sending the case back for... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal

Performance

YTD
-7.99%
-7.99%
1 Month
+1.95%
+1.95%
3 Month
-5.51%
-5.51%
6 Month
-5.73%
-5.73%
1 Year
-10.05%
-10.05%

More News

Read More
Johnson & Johnson's Options: A Look at What the Big Money is Thinking
Via Benzinga
The Top 3 Sectors Poised For Growth This Summer
Via MarketBeat
Topics ETFs
NYSE:JNJ, an undervalued stock with good fundamentals.
Via Chartmill
Market Analysis: Johnson & Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
In-Depth Examination Of 11 Analyst Recommendations For Johnson & Johnson
Via Benzinga
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
Via The Motley Fool
2 Top Stocks to Buy Now for Years of Passive Income
Via The Motley Fool
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Faces New Lawsuit(s) Related To Its Talc Products
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme
From Beasley Allen
Via Business Wire
Johnson & Johnson's Arthritis Drug Shows Potential In Crohn's Disease
Via Benzinga
3 Healthcare Stocks to Buy Now: June 2024
Via InvestorPlace
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
Via InvestorPlace
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Via The Motley Fool
3 No-Brainer Stocks to Buy With $500 Right Now
Via The Motley Fool
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
Via Benzinga
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products
From Beasley Allen
Via Business Wire
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Via Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Via Benzinga
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
Via FinancialNewsMedia
The 7 Best Under $20 Stocks to Buy in June 2024
Via InvestorPlace
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
From FN Media Group LLC
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.